As both disease-associated BRCA2 mutation carriers were Caucasian, the prevalence of such mutations in whites is 0.78% (95%CI 0.09–2.81%); the estimated RR of prostate cancer is 7.8 (95%CI 1.8–9.4) in Caucasian BRCA2 mutation carriers. The gene discussed is BRCA2; the disease is prostate carcinoma.